A CME Satellite Symposium held at the Virtual Annual Scientific Meeting of the Heart Failure Society of America Emerging Issues in Cardiac Amyloidosis: Moving from rare and fatal, to a treatable chronic cardiovascular disease Sunday, October 4, 2020 • 1:30 - 2:45 pm EDT Accredited Sponsor: Heart Failure Society of America Supported by independent medical education grants from Pfizer, Alnylam, and the Amyloidosis Research Consortium. This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee. SYMPOSIUM AGENDA 1:30 PM Welcome and Introduction • Martha Grogan and Mathew Maurer 1:35 PM Early Identification of Cardiac Amyloidosis and Monitoring Disease Progression • Ahmad Masri 1:50 PM Emerging Therapies for AL Cardiac Amyloidosis • Ray Comenzo 2:05 PM Neurologic Assessment for Early Diagnosis and Appropriate Therapy • Sami Khella 2:20 PM EP Issues in Cardiac Amyloidosis • Wael Jaber 2:35 PM Open audience Q&A with Panel • All Faculty 2:45 PM Adjourn LEARNING OBJECTIVES Following this activity, participants will be able to: • Define evaluation components necessary to improve early identification of cardiac amyloidosis. • Review emerging therapies for AL cardiac amyloidosis including monitoring for disease progression. • Describe common neurological symptoms and the role of the cardiologist in assessing for neurologic involvement. • Identify indications and contraindications for antiarrhythmic therapies in amyloidosis patients with atrial fibrillation and other arrhythmias. PROGRAM CO-CHAIRS Martha Grogan, MD Associate Professor of Medicine Consultant, Division of Cardiovascular Diseases Director, Cardiac Amyloid Clinic Mayo Clinic Rochester, MN Mathew S. Maurer, MD Professor of Medicine Arnold and Arlene Goldstein Professor of Cardiology Director, Clinical Cardiovascular Research Laboratory for the Elderly Columbia University Medical Center / New York Presbyterian Hospital New York, NY FACULTY Ahmad Masri, MD, MS Co-Director, OHSU Amyloidosis Center Assistant Professor of Medicine Knight Cardiovascular Institute Oregon Health & Science University Portland, OR Raymond Comenzo, MD Professor of Medicine Tufts University School of Medicine Attending Physician Division of Hematology-Oncology Department of Medicine Tufts Medical Center, Boston, MA Sami Khella, MD Professor and Chief of Neurology Penn Presbyterian Medical Center University of Pennsylvania Philadelphia, PA Wael A. Jaber, MD, FACC, FESC Professor of Medicine Cleveland Clinic Lerner College of Medicine Fuad Jubran Endowed Chair in Cardiovascular Medicine Heart and Vascular Institute Cleveland Clinic, Cleveland, OH ACCREDITATION Physicians: Accreditation Statement: In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity. Nurses: This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity. ELIGIBILITY Registration for the HFSA Virtual Annual Scientific Meeting is required to attend this symposium.

Emerging Issues in Cardiac Amyloidosis

Download PDF Report

Upload
others
View
4
Download
0

Embed Size (px)

Citation preview

Page 1: Emerging Issues in Cardiac Amyloidosis

A CME Satellite Symposium held at the Virtual Annual Scientific Meeting of the Heart Failure Society of America

Emerging Issues inCardiac Amyloidosis: Moving from rare and fatal, to a treatablechronic cardiovascular disease

Sunday, October 4, 2020 • 1:30 - 2:45 pm EDT

Accredited Sponsor: Heart Failure Society of AmericaSupported by independent medical education grants from Pfi zer, Alnylam, and the Amyloidosis Research Consortium.

This satellite symposium is not part of the scientifi c program as planned by the Heart Failure Society of America Program Committee.

SYMPOSIUM AGENDA1:30 PM Welcome and Introduction

• Martha Grogan and Mathew Maurer

1:35 PM Early Identifi cation of Cardiac Amyloidosis and Monitoring Disease Progression

• Ahmad Masri

1:50 PM Emerging Therapies for AL Cardiac Amyloidosis• Ray Comenzo

2:05 PM Neurologic Assessment for Early Diagnosis and Appropriate Therapy • Sami Khella

2:20 PM EP Issues in Cardiac Amyloidosis • Wael Jaber

2:35 PM Open audience Q&A with Panel • All Faculty

2:45 PM Adjourn

LEARNING OBJECTIVESFollowing this activity, participants will be able to:

• Defi ne evaluation components necessary to improve early identifi cation of cardiac amyloidosis.

• Review emerging therapies for AL cardiac amyloidosis including monitoring for disease progression.

• Describe common neurological symptoms and the role of the cardiologist in assessing for neurologic involvement.

• Identify indications and contraindications for antiarrhythmic therapies in amyloidosis patients with atrial fi brillation and other arrhythmias.

PROGRAM CO-CHAIRSMartha Grogan, MDAssociate Professor of MedicineConsultant, Division of Cardiovascular DiseasesDirector, Cardiac Amyloid ClinicMayo ClinicRochester, MN

Mathew S. Maurer, MDProfessor of MedicineArnold and Arlene Goldstein Professor of CardiologyDirector, Clinical Cardiovascular Research Laboratory for the ElderlyColumbia University Medical Center / New York Presbyterian HospitalNew York, NY

FACULTYAhmad Masri, MD, MSCo-Director, OHSU Amyloidosis Center Assistant Professor of Medicine Knight Cardiovascular Institute Oregon Health & Science UniversityPortland, OR

Raymond Comenzo, MDProfessor of Medicine Tufts University School of MedicineAttending Physician Division of Hematology-OncologyDepartment of Medicine Tufts Medical Center, Boston, MA

Sami Khella, MDProfessor and Chief of NeurologyPenn Presbyterian Medical CenterUniversity of PennsylvaniaPhiladelphia, PA

Wael A. Jaber, MD, FACC, FESCProfessor of MedicineCleveland Clinic Lerner College of MedicineFuad Jubran Endowed Chair in Cardiovascular MedicineHeart and Vascular InstituteCleveland Clinic, Cleveland, OH

ACCREDITATIONPhysicians:Accreditation Statement: In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.Nurses:This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

ELIGIBILITYRegistration for the HFSA Virtual Annual Scientifi c Meeting is required to attend this symposium.